{"disease":{"id":"astrocytoma","name":"astrocytoma"},"drugs":{"marketed":[{"drug_id":"everolimus","indication_name":"Subependymal Giant Cell Astrocytoma associated with Tuberous Sclerosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Afinitor","generic_name":"everolimus","company_name":"Novartis","drug_phase":"marketed","molecular_target":"Serine/threonine-protein kinase mTOR","drug_class":"Kinase Inhibitor [EPC]","quality_score":67,"revenue":"600","mechanism":"Afinitor works by blocking the mTOR protein, which is involved in cell growth and division."},{"drug_id":"afinitor","indication_name":"Subependymal Giant Cell Astrocytoma associated with Tuberous Sclerosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Afinitor","company_name":"Central European Society for Anticancer Drug Research","drug_phase":"marketed","molecular_target":"Multidrug resistance protein 1, Peptidyl-prolyl cis-trans isomerase FKBP1A, Serine/threonine-protein kinase mTOR","drug_class":"","quality_score":19,"revenue":null,"mechanism":null},{"drug_id":"temodal","indication_name":"Astrocytoma, anaplastic","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Temodal","company_name":"Armando Santoro, MD","drug_phase":"phase_1","molecular_target":"","drug_class":"","quality_score":3,"revenue":null,"mechanism":null},{"drug_id":"vorasidenib","indication_name":"Grade 2 astrocytoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Voranigo","generic_name":"VORASIDENIB","company_name":"Servier","drug_phase":"marketed","molecular_target":"","drug_class":"Isocitrate Dehydrogenase 1 Inhibitor [EPC]","quality_score":50,"revenue":null,"mechanism":"Voranigo works by blocking the activity of an enzyme called isocitrate dehydrogenase 1."},{"drug_id":"temozolomide","indication_name":"Astrocytoma, anaplastic","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Temodar","generic_name":"temozolomide","company_name":"Merck & Co.","drug_phase":"marketed","molecular_target":"","drug_class":"Alkylating Drug [EPC]","quality_score":10,"revenue":null,"mechanism":"Temodar works by attaching an alkyl group to the DNA of cancer cells, interfering with their ability to replicate and ultimately leading to cell death."}],"pipeline":[],"offLabel":[],"totalMarketed":5,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT00009035","title":"Natural History of Patients With Brain and Spinal Cord Tumors","phase":"","overall_status":"COMPLETED","enrollment_count":3050,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT04648462","title":"Proton Therapy Research Infrastructure- ProTRAIT- Neuro-oncology","phase":"","overall_status":"RECRUITING","enrollment_count":1500,"lead_sponsor_name":"Maastricht Radiation Oncology","has_results":false},{"nct_id":"NCT00919750","title":"Collecting and Storing Blood and Brain Tumor Tissue Samples From Children With Brain Tumors","phase":"","overall_status":"COMPLETED","enrollment_count":1258,"lead_sponsor_name":"Children's Oncology Group","has_results":false},{"nct_id":"NCT07448480","title":"Comprehensive Analysis of Chemotherapy and Targeted Therapy Outcomes in Recurrent Malignant Gliomas","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":1000,"lead_sponsor_name":"Blokhin's Russian Cancer Research Center","has_results":false},{"nct_id":"NCT06620926","title":"Impact of IDH Mutation and Adjuvant Chemo(radio)therapy on Survival Outcome in Grade II/III Astrocytoma","phase":"","overall_status":"COMPLETED","enrollment_count":811,"lead_sponsor_name":"asmaa salama ibrahim","has_results":false},{"nct_id":"NCT06118723","title":"The SUPRAMAX Study: Supramaximal Resection Versus Maximal Resection for High-Grade Glioma Patients (ENCRAM 2201)","phase":"","overall_status":"RECRUITING","enrollment_count":784,"lead_sponsor_name":"Jasper Gerritsen","has_results":false},{"nct_id":"NCT00035373","title":"Eligibility Screening of Patients With Central Nervous System Tumors for the National Cancer Institute s (NCI) Clinical Research Protocols","phase":"","overall_status":"TERMINATED","enrollment_count":767,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT03722355","title":"Hyperfractionated RT With BCNU Versus Conventional RT With BCNU for Supratentorial Malignant Glioma","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":712,"lead_sponsor_name":"Radiation Therapy Oncology Group","has_results":false},{"nct_id":"NCT00031538","title":"Genetic Analysis of Brain Tumors","phase":"","overall_status":"TERMINATED","enrollment_count":674,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT05624736","title":"Hierarchical Diagnosis for Adult Diffuse Glioma Based on Deep Learning","phase":"","overall_status":"UNKNOWN","enrollment_count":500,"lead_sponsor_name":"The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School","has_results":false},{"nct_id":"NCT06809322","title":"Vorasidenib Maintenance for IDH Mutant Astrocytoma","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":468,"lead_sponsor_name":"European Organisation for Research and Treatment of Cancer - EORTC","has_results":false},{"nct_id":"NCT06283927","title":"The RECSUR-study: Resection Versus Best Oncological Treatment for Recurrent Glioblastoma (ENCRAM 2302)","phase":"","overall_status":"RECRUITING","enrollment_count":464,"lead_sponsor_name":"Jasper Gerritsen","has_results":false},{"nct_id":"NCT02414165","title":"The Toca 5 Trial: Toca 511 & Toca FC Versus Standard of Care in Patients With Recurrent High Grade Glioma","phase":"PHASE2, PHASE3","overall_status":"TERMINATED","enrollment_count":403,"lead_sponsor_name":"Tocagen Inc.","has_results":false},{"nct_id":"NCT05303519","title":"SIGMA (Safusidenib in IDH1 Mutant Glioma Maintenance)","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":365,"lead_sponsor_name":"Nuvation Bio Inc.","has_results":false},{"nct_id":"NCT05839379","title":"Targeted Pediatric High-Grade Glioma Therapy","phase":"","overall_status":"RECRUITING","enrollment_count":350,"lead_sponsor_name":"Nationwide Children's Hospital","has_results":false},{"nct_id":"NCT05229198","title":"ALBATROSS Study: International Multicenter Study for Prospective Validation of Imaging Biomarkers Calculated at Vascular Habitats of High-grade Gliomas","phase":"","overall_status":"COMPLETED","enrollment_count":300,"lead_sponsor_name":"Juan M Garcia-Gomez","has_results":false},{"nct_id":"NCT04576117","title":"A Study to Compare Treatment With the Drug Selumetinib Alone Versus Selumetinib and Vinblastine in Patients With Recurrent or Progressive Low-Grade Glioma","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":300,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT05934630","title":"Testing Cerebrospinal Fluid for Cell-free Tumor DNA in Children, Adolescents, and Young Adults With Brain Tumors","phase":"","overall_status":"SUSPENDED","enrollment_count":300,"lead_sponsor_name":"Pediatric Brain Tumor Consortium","has_results":false},{"nct_id":"NCT03861299","title":"The SAFE-Trial: Awake Craniotomy Versus Surgery Under General Anesthesia for Glioblastoma Patients.","phase":"NA","overall_status":"RECRUITING","enrollment_count":246,"lead_sponsor_name":"Jasper Gerritsen","has_results":false},{"nct_id":"NCT05190172","title":"PRO-GLIO: PROton Versus Photon Therapy in IDH-mutated Diffuse Grade II and III GLIOmas","phase":"NA","overall_status":"RECRUITING","enrollment_count":225,"lead_sponsor_name":"Oslo University Hospital","has_results":false},{"nct_id":"NCT06273176","title":"The RECMAP-study: Resection With or Without Intraoperative Mapping for Recurrent Glioblastoma","phase":"","overall_status":"RECRUITING","enrollment_count":225,"lead_sponsor_name":"Erasmus Medical Center","has_results":false},{"nct_id":"NCT01089101","title":"Selumetinib in Treating Young Patients With Recurrent or Refractory Low Grade Glioma","phase":"PHASE1, PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":217,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT06885333","title":"Whole-Brain Tumor Burden Metrics with Inflammatory and Molecular Markers to Predict Postoperative Neurocognitive Decline in Glioma","phase":"","overall_status":"COMPLETED","enrollment_count":192,"lead_sponsor_name":"West China Hospital","has_results":false},{"nct_id":"NCT06630260","title":"5G-RUBY: Avutometinib and Defactinib in Malignant Brain Tumours","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":182,"lead_sponsor_name":"Institute of Cancer Research, United Kingdom","has_results":false},{"nct_id":"NCT02655601","title":"Trial of Newly Diagnosed High Grade Glioma Treated With Concurrent Radiation Therapy, Temozolomide and BMX-001","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":177,"lead_sponsor_name":"BioMimetix JV, LLC","has_results":true},{"nct_id":"NCT02465268","title":"Vaccine Therapy for the Treatment of Newly Diagnosed Glioblastoma Multiforme","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":175,"lead_sponsor_name":"University of Florida","has_results":true},{"nct_id":"NCT04166409","title":"A Study of the Drugs Selumetinib vs. Carboplatin and Vincristine in Patients With Low-Grade Glioma","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":170,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT03243461","title":"International Cooperative Phase III Trial of the HIT-HGG Study Group (HIT-HGG-2013)","phase":"PHASE3","overall_status":"UNKNOWN","enrollment_count":167,"lead_sponsor_name":"University of Göttingen","has_results":false},{"nct_id":"NCT04028479","title":"The Registry of Oncology Outcomes Associated With Testing and Treatment","phase":"","overall_status":"COMPLETED","enrollment_count":167,"lead_sponsor_name":"Taproot Health","has_results":false},{"nct_id":"NCT03975829","title":"Pediatric Long-Term Follow-up and Rollover Study","phase":"PHASE4","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":163,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":false},{"nct_id":"NCT00335075","title":"Efficacy and Safety of Temodal vs Semustine in Subjects With Recurrent Glioblastoma or Anaplastic Astrocytoma (Study P03644)","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":151,"lead_sponsor_name":"Merck Sharp & Dohme LLC","has_results":false},{"nct_id":"NCT02684058","title":"Study of Efficacy and Safety of Dabrafenib in Combination With Trametinib in Pediatric Patients With BRAF V600 Mutation Positive LGG or Relapsed or Refractory HGG Tumors","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":151,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":true},{"nct_id":"NCT05180825","title":"Pediatric Low Grade Glioma - MEKinhibitor TRIal vs Chemotherapy","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":134,"lead_sponsor_name":"University Hospital, Strasbourg, France","has_results":false},{"nct_id":"NCT06047379","title":"Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":134,"lead_sponsor_name":"Neonc Technologies, Inc.","has_results":false},{"nct_id":"NCT00392171","title":"The Effects of Continuous 28-day (28/28) Temozolomide Chemotherapy in Subjects With Recurrent Malignant Glioma Who Have Failed the Conventional 5-day (5/28) Treatment (P04601)","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":120,"lead_sponsor_name":"Merck Sharp & Dohme LLC","has_results":true},{"nct_id":"NCT05843253","title":"Study of Ribociclib and Everolimus in HGG and DIPG or Ribociclib and Temozolomide in DHG, H3G34-mutant","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":120,"lead_sponsor_name":"Nationwide Children's Hospital","has_results":false},{"nct_id":"NCT03180502","title":"Proton Beam or Intensity-Modulated Radiation Therapy in Preserving Brain Function in Patients With IDH Mutant Grade II or III Glioma","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":120,"lead_sponsor_name":"NRG Oncology","has_results":false},{"nct_id":"NCT00100802","title":"Radiation Therapy, Temozolomide, and Lomustine in Treating Young Patients With Newly Diagnosed Gliomas","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":118,"lead_sponsor_name":"Children's Oncology Group","has_results":true},{"nct_id":"NCT06989086","title":"FearLess in NeuroOncology","phase":"NA","overall_status":"RECRUITING","enrollment_count":112,"lead_sponsor_name":"Virginia Commonwealth University","has_results":false},{"nct_id":"NCT01236560","title":"Vorinostat, Temozolomide, or Bevacizumab in Combination With Radiation Therapy Followed by Bevacizumab and Temozolomide in Young Patients With Newly Diagnosed High-Grade Glioma","phase":"PHASE2, PHASE3","overall_status":"COMPLETED","enrollment_count":101,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":true},{"nct_id":"NCT07159607","title":"Amino Acid PET-based Response Assessment in IDH-mutant Gliomas (APPEAR)","phase":"","overall_status":"RECRUITING","enrollment_count":100,"lead_sponsor_name":"LMU Klinikum","has_results":false},{"nct_id":"NCT03900689","title":"Social Determinants of Health in Glioblastoma Population","phase":"","overall_status":"COMPLETED","enrollment_count":100,"lead_sponsor_name":"Wake Forest University Health Sciences","has_results":false},{"nct_id":"NCT01849952","title":"Evaluating the Expression Levels of MicroRNA-10b in Patients With Gliomas","phase":"","overall_status":"TERMINATED","enrollment_count":94,"lead_sponsor_name":"Dartmouth-Hitchcock Medical Center","has_results":false},{"nct_id":"NCT00268385","title":"Vorinostat and Temozolomide in Treating Patients With Malignant Gliomas","phase":"PHASE1","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":83,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT04304300","title":"Radiotherapy in IDH Mutated Glioma: Evaluation of Late Outcomes","phase":"","overall_status":"COMPLETED","enrollment_count":80,"lead_sponsor_name":"Erasmus Medical Center","has_results":false},{"nct_id":"NCT01189266","title":"Vorinostat and Radiation Therapy Followed by Maintenance Therapy With Vorinostat in Treating Younger Patients With Newly Diagnosed Diffuse Intrinsic Pontine Glioma","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":79,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":true},{"nct_id":"NCT05600491","title":"A Phase III Study of Postoperative Early Temozolomide Treatment Plus STUPP Regimen for Newly Diagnosed GBM Multiforme","phase":"PHASE3","overall_status":"UNKNOWN","enrollment_count":78,"lead_sponsor_name":"Sun Yat-sen University","has_results":false},{"nct_id":"NCT01553149","title":"Low-Dose or High-Dose Lenalidomide in Treating Younger Patients With Recurrent, Refractory, or Progressive Pilocytic Astrocytoma or Optic Pathway Glioma","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":75,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":true},{"nct_id":"NCT03224104","title":"Multi-kinase Inhibitor TG02 (TG02) in Elderly Newly Diagnosed or Adult Relapsed Patients With Anaplastic Astrocytoma or Glioblastoma.","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":71,"lead_sponsor_name":"European Organisation for Research and Treatment of Cancer - EORTC","has_results":true},{"nct_id":"NCT06439420","title":"CBT-I in Primary Brain Tumor Patients: Phase IIc Randomized Feasibility Pilot Trial","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":70,"lead_sponsor_name":"Virginia Commonwealth University","has_results":false}],"total":50},"guidelines":[],"source":"Drug Landscape verified database"}